winestriada.blogg.se

Ebere illustrate
Ebere illustrate







  1. #EBERE ILLUSTRATE HOW TO#
  2. #EBERE ILLUSTRATE DOWNLOAD#

North West University, Mafikeng, South Africaĭepartment of Law, Niger Delta University, Nigeria

#EBERE ILLUSTRATE DOWNLOAD#

If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.įor technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Ana Poveda (email available below). If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form. It also allows you to accept potential citations to this item that we are uncertain about. This allows to link your profile to this item. If you have authored this item and are not yet registered with RePEc, we encourage you to do it here.

#EBERE ILLUSTRATE HOW TO#

See general information about how to correct material in RePEc.įor technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact. When requesting a correction, please mention this item's handle: RePEc:cte:werepe:we036827. You can help correct errors and omissions. 12(12), pages 1-12, December.Īll material on this site has been provided by the respective publishers and authors. PLOS ONE, Public Library of Science, vol. " Is quality of life different between diabetic and non-diabetic people? The importance of cardiovascular risks,"

  • L M Peña-Longobardo & B Rodríguez-Sánchez & M Mata-Cases & L Rodríguez-Mañas & M Capel & J Oliva-Moreno, 2017.
  • " Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran,"
  • Mehdi Javanbakht & Hamid R Baradaran & Atefeh Mashayekhi & Ali Akbar Haghdoost & Mohammad E Khamseh & Erfan Kharazmi & Aboozar Sadeghi, 2011.
  • " The Economic Costs of Type 2 Diabetes: A Global Systematic Review,"
  • Till Seuring & Olga Archangelidi & Marc Suhrcke, 2015.
  • Health Economics, John Wiley & Sons, Ltd., vol. " The effect of diabetes on female labor force decisions: new evidence from the National Health Interview Survey," " Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain," Ampudia-Blasco & Belén Martínez-Lage Álvarez & Isabel Pérez Escolano & Gonzalo París, 2006.
  • Ebere Akobundu & Jing Ju & Lisa Blatt & C.
  • The European Journal of Health Economics, Springer Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol.

    ebere illustrate

  • Juan Oliva-Moreno & Julio López-Bastida & Rubén Osuna-Guerrero & Angel Montejo-González & Beatriz Duque-González, 2006.
  • " Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain,"Īpplied Health Economics and Health Policy, Springer, vol.
  • Tatiana Dilla & Amparo Valladares & Claudia Nicolay & Javier Salvador & Jesús Reviriego & María Costi, 2012.
  • " Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014," Eriksson & Thomas Nyström & Anna Norhammar & Urban Olsson & Johan Bodegård, 2018.
  • David Nathanson & Ugne Sabale & Jan W.
  • Likewise, they illustrate the magnitude of the costs of treatment of DM-related complications. Despite our rather conservative approach to the issue, our findings demonstrate the high direct healthcare costs of diabetic patients. The per-diabetic, per-year cost ranges between (euros)1,290 to 1,476. Much lower are the costs of insulin and oral hypoglycemic agents ((euros)311 million), primary care visits ((euros)181-272 million), specialized visits ((euros)127-145 million) and disposable elements ((euros)70-81 million). Hospital costs had the highest weight ((euros)933 million) in the total, followed by non-insulin, non-hypoglycemic-agent drugs ((euros)777-932 million). The estimated direct cost of DM during the year 2002 ranges from (euros)2.4 billion to (euros)2.67 billion. The total cost was composed of six items: insulin and oral hypoglycemic agents other drugs disposable and consumable goods (glucose test strips, needles and syringes) hospitalization primary care visits visits to specialists. A range of prevalence from 5% to 6% of the adult population was determined. Direct healthcare costs were estimated using rates of DM, based on primary and secondary sources of information. The present work is a cost-of-illness study. To estimate the healthcare resources spent by diabetic patients in Spain during the year 2002.









    Ebere illustrate